Depression

Ketamine EEG Alpha Redundancy Tracked Depression Response in Late-Life TRD

July 10, 2026 by BrainASAP

TL;DR: A 2026 study in Translational Psychiatry found that ketamine changed EEG-derived high-order brain interactions in late-life treatment-resistant depression, and a 24-hour increase in alpha-band redundancy tracked greater depression improvement by Day 7. Key Findings 30 analyzed participants: The secondary analysis compared 18 ketamine-treated and 12 midazolam-treated late-life veterans with treatment-resistant depression at baseline. Single …

Review Identified Different Depression Treatment Targets in Alzheimer’s and Parkinson’s

July 10, 2026 by BrainASAP

TL;DR: A 2026 narrative review in Molecular Psychiatry argues that depression in Alzheimer’s disease and Parkinson’s disease follows disease-specific brain mechanisms, while standard antidepressant evidence remains weak in these neurodegenerative populations. Key Findings 42% in Alzheimer’s disease: The review cites depressive syndromes affecting about 42% of patients with Alzheimer’s disease and 35% of patients with …

AI Chatbots Did Not Significantly Reduce Depression Symptoms in Meta-Analysis

July 10, 2026 by BrainASAP

TL;DR: A 2026 meta-analysis in Journal of Medical Internet Research did not find a statistically significant reduction in Patient Health Questionnaire-9 (PHQ-9) depression scores with AI-driven chatbots, but emotionally responsive, structured, and frequent interactions were more consistently associated with user adherence. Key Findings 11 randomized trials: The review included 11 RCTs with 2220 participants for …

Olanzapine-Samidorphan Linked to Depressive Symptoms in Case Report

July 10, 2026 by BrainASAP

TL;DR: A 2026 study in International Clinical Psychopharmacology described a 40-year-old man whose dysphoria, anhedonia, amotivation, and fatigue appeared soon after olanzapine was changed to olanzapine-samidorphan and resolved after he returned to olanzapine alone. Key Findings One-patient case report: The report followed a 40-year-old man after first psychiatric hospitalization, so the evidence is a clinical …

Depression Transition Risk Increased After Bipolar Manic or Mixed Episodes

July 10, 2026 by BrainASAP

TL;DR: A 2026 medRxiv retrospective cohort study found that depression often followed bipolar manic or mixed episodes quickly, with 25% of manic episodes and 22% of mixed episodes transitioning to depression within 1 month. Key Findings First-month risk window: Researchers analyzed 10,437 people, 42,314 mood episodes, and 90,727 person-years in a U.S. electronic health record …

Subcutaneous Ketamine Response Faded After Treatment-Resistant Depression Extension

July 10, 2026 by BrainASAP

TL;DR: A 2026 study in The British Journal of Psychiatry found that 4 weeks of twice-weekly subcutaneous racemic ketamine helped a minority of people with treatment-resistant depression, but response fell from 30% at treatment end to 17% 4 weeks later. Key Findings 130 trial participants entered the extension: All had treatment-resistant depression and a Montgomery-Asberg …

Connectivity-Guided iTBS Improved Inpatient Treatment-Resistant Depression Scores

July 8, 2026 by BrainASAP

TL;DR: A 2026 randomized trial posted to medRxiv found that connectivity-guided accelerated intermittent theta-burst stimulation added to inpatient care improved treatment-resistant depression scores more than sham stimulation over 2 weeks. Key Findings 57 randomized patients: Hospitalized adults with unipolar treatment-resistant depression were assigned to active or sham stimulation. 30 iTBS sessions: Active treatment delivered 3 …

Neuroinflammation Review Linked CRP and IL-6 to Depression Subtype

July 7, 2026 by BrainASAP

TL;DR: A 2026 review in Translational Psychiatry argues for a biologically meaningful inflammatory depression subgroup, with CRP, IL-6, TNF-alpha, glial activation, kynurenine metabolism, and synaptic plasticity linking immune signaling to symptoms and treatment response. Key Findings One-third treatment gap: The review notes that current pharmacological treatments fail to produce adequate responses in approximately one-third of …

EMBER-MDD Will Test Multi-Omic Biomarkers for Esketamine Response

July 7, 2026 by BrainASAP

TL;DR: A 2026 methodology paper in European Archives of Psychiatry and Clinical Neuroscience describes EMBER-MDD, a research-only multi-omic study designed to find treatment-resistance and esketamine-response biomarkers in about 420 adults with major depressive disorder. Key Findings About 420 adults: EMBER-MDD will analyze biomaterials from approximately 420 adults with major depressive disorder. 210 versus 210 design: …

Childhood Abuse Timing Linked to Hippocampus and Amygdala Emotion Responses

July 6, 2026 by BrainASAP

TL;DR: A 2026 fMRI study in Molecular Psychiatry linked abuse before age 13 to stronger hippocampal responses during non-conscious negative emotion processing, while abuse during adolescence was linked to stronger amygdala responses during conscious emotion viewing. Key Findings Timing split the limbic response: The sample included 635 adults after exclusions and quality checks, including people …

+ Load more